C

이연제약

102460KOSPI

52.8 / 100

Reference Date: 2026-09-08

Financial Score16.5 / 40
News Sentiment21.3 / 25
Momentum5.0 / 20
Disclosure10.0 / 15
AI Analysis: the debt ratio is very low with excellent financial health but ROE is below the industry average. Roughly flat over the past month, and news sentiment is neutral.

Company InformationBased on 2025 Annual Report

Business Overview

Il Yeon Pharm is a specialized pharmaceutical company established in 1964, focusing on the manufacturing and sales of prescription drugs, original pharmaceuticals (e.g., CT contrast agent 'Optirey'), and bulk drugs. Its Chungju facility, certified for biopharmaceutical production and CMO services, supports new drug pipeline development through a production-platform-based R&D model. However, as of 2024, the company reported sales of 145.9 billion won, an operating loss of 30.3 billion won, and a net loss of 29.6 billion won, indicating the need for improved profitability.

Number of Employees

457people

Average Salary

76.4M KRW

Score Calculation Basis

Detailed Financial Score

PER
Industry Average 15.004.0Point
PBR
0.84Industry Average 1.205.5Point

Lower than industry avg (good)

ROE
-12.60Industry Average 8.000.0Point

Well below industry avg

Debt Ratio
46.08Industry Average 100.006.5Point

Half of industry avg (excellent)

Trend 2023~20250.5 / 10 points
Revenue Growth Rate
0.5 / 3

Avg ▼1.7% (2-year basis)

Operating Profit Growth Rate
0.0 / 3

Avg ▼19193.7% (2-year basis)

ROE Trend
0.0 / 4

Avg ROE -3.2% (declining, 3yr)

Detailed News Sentiment

2 totalPositive 2Neutral 0Negative 0Average Sentiment Score 85

Detailed Momentum

52-week position1.0Point

Near 52w low (6%, downtrend)

Current 9,940Won52-week high 12,57052-week low 9,770
1-month return3.0Point

1m -0.9% (flat)

Volume trend1.0Point

Volume decreasing

Detailed Disclosure

1 totalPositive 0Neutral 1Negative 0
  • Neutral반기보고서 (2026.06)2026-08-14